Oncology| Volume 73, ISSUE 3, P620-623, March 2009

Download started.


Does Race Affect Postoperative Outcomes in Patients With Low-Risk Prostate Cancer Who Undergo Radical Prostatectomy?

Published:December 18, 2008DOI:


      To assess the magnitude of racial disparities in prostate cancer outcomes following radical prostatectomy for low-risk prostate cancer.


      We retrospectively reviewed our database of 2407 patients who under went radical prostatectomy and isolated 2 cohorts of patients with low-risk prostate cancer. Cohort 1 was defined using liberal criteria, and cohort 2 was isolated using more stringent criteria. We then studied pre- and postoperative parameters to discern any racial differences in these 2 groups. Statistical analyses, including log-rank, χ2, and Fisher's exact analyses, were used to ascertain the significance of such differences.


      Preoperatively, no significant differences were found between the white and African-American patients with regard to age at diagnosis, mean prostate-specific antigen, median follow-up, or percentage of involved cores on prostate biopsy. African-American patients in cohort 1 had a greater mean body mass index than did white patients (26.9 vs 27.8, P = .026). The analysis of postoperative data demonstrated no significant difference between white and African-American patients in the risk of biochemical failure, extraprostatic extension, seminal vesicle involvement, positive surgical margins, tumor volume, or risk of disease upgrading. African-American patients in cohort 2 demonstrated greater all-cause mortality compared with their white counterparts (9.4% vs 3.1%, P = .027).


      In patients with low-risk prostate cancer treated with radical prostatectomy, there exist no significant differences in surrogate measures of disease control, risk of disease upgrading, estimated tumor volume, or recurrence-free survival between whites and African-Americans.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jemal A.
        • Murray T.
        • Ward E.
        • et al.
        Cancer statistics, 2005.
        CA Cancer J Clin. 2005; 55: 10-30
        • Landis S.H.
        • Murray T.
        • Bolden S.
        • et al.
        Cancer statistics, 1998.
        CA Cancer J Clin. 1998; 48: 6-29
        • Cooperberg M.R.
        • Moul J.W.
        • Carroll P.R.
        The changing face of prostate cancer.
        J Clin Oncol. 2005; 23: 8146-8151
        • Draisma G.
        • Boer R.
        • Otto S.J.
        • et al.
        Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer.
        J Natl Cancer Inst. 2003; 95: 868-878
        • Epstein J.I.
        • Walsh P.C.
        • Carmichael M.
        • et al.
        Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
        JAMA. 1994; 271: 368-374
        • Pettaway C.A.
        • Troncoso P.
        • Ramirez E.I.
        • et al.
        Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens.
        J Urol. 1998; 160: 437-442
        • Sakr W.A.
        • Grignon D.J.
        • Haas G.P.
        • et al.
        Epidemiology of high grade prostatic intraepithelial neoplasia.
        Pathol Res Pract. 1995; 191: 838-841
        • Moul J.W.
        • Connelly R.R.
        • Mooneyhan R.M.
        • et al.
        Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients.
        J Urol. 1999; 162: 394-397
        • Sanchez-Ortiz R.F.
        • Troncoso P.
        • Babaian R.J.
        • et al.
        African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men.
        Cancer. 2006; 107: 75-82
        • Robbins A.S.
        • Yin D.
        • Parikh-Patel A.
        Differences in prognostic factors and survival among white men and black men with prostate cancer, California, 1995-2004.
        Am J Epidemiol. 2007; 166: 71-78
        • Choo R.
        • Klotz L.
        • Danjoux C.
        • et al.
        Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
        J Urol. 2002; 167: 1664-1669
        • Klotz L.
        Active surveillance for prostate cancer: for whom?.
        J Clin Oncol. 2005; 23: 8165-8169
        • Guzzo T.J.
        • Vira M.A.
        • Neway W.
        • et al.
        Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy.
        Urology. 2007; 69: 1147-1151
        • D'Amico A.V.
        • Whittington R.
        • Malkowicz S.B.
        • et al.
        Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
        JAMA. 1998; 280: 969-974
        • Kattan M.W.
        • Eastham J.A.
        • Stapleton A.M.
        • et al.
        A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.
        J Natl Cancer Inst. 1998; 90: 766-771
        • Thompson I.M.
        • Pauler D.K.
        • Goodman P.J.
        • et al.
        Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
        N Engl J Med. 2004; 350: 2239-2246
        • Albertsen P.C.
        • Hanley J.A.
        • Fine J.
        20-Year outcomes following conservative management of clinically localized prostate cancer.
        JAMA. 2005; 293: 2095-2101
        • Platz E.A.
        • Rimm E.B.
        • Willett W.C.
        • et al.
        Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals.
        J Natl Cancer Inst. 2000; 92: 2009-2017
        • Moul J.W.
        • Douglas T.H.
        • McCarthy W.F.
        • et al.
        Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting.
        J Urol. 1996; 155: 1667-1673
        • Freedland S.J.
        • Dorey F.
        • Aronson W.J.
        Multivariate analysis of race and adverse pathologic findings after radical prostatectomy.
        Urology. 2000; 56: 807-811
        • Freedland S.J.
        • Jalkut M.
        • Dorey F.
        • et al.
        Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.
        Urology. 2000; 56: 87-91
        • Powell I.J.
        • Banerjee M.
        • Novallo M.
        • et al.
        Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease.
        Urology. 2000; 55: 246-251
        • Carter H.B.
        • Kettermann A.
        • Warlick C.
        • et al.
        Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.
        J Urol. 2007; 178: 2359-2365
        • Warlick C.
        • Trock B.J.
        • Landis P.
        • et al.
        Delayed versus immediate surgical intervention and prostate cancer outcome.
        J Natl Cancer Inst. 2006; 98: 355-357